Hematopoiesis News Volume 2.34 | Aug 30 2011

LABORATORY RESEARCH

JAM-B Regulates Maintenance of Hematopoietic Stem Cells in the Bone Marrow
Here, scientists show that hematopoietic stem cells adhere to JAM-B (junctional adhesion molecule-B) expressed by bone marrow stromal cells in a JAM-C dependent manner. [Blood] Abstract

Ontogeny Stage-Independent and High-Level Clonal Expansion In Vitro of Mouse Hematopoietic Stem Cells Stimulated by an Engineered NUP98-HOX Fusion Transcription Factor
Here investigators couple the ability of engineered NUP98-HOXA10hd expression to stimulate >1,000-fold net expansions of murine hematopoietic stem cells (HSCs) in 10-day cultures initiated with bulk lin^–Sca-1⁺c-kit⁺ cells, with strategies to purify fetal and adult HSCs and analyze their expansion clonally. [Blood] Abstract

RUNX1 Regulates the CD34 Gene in Hematopoietic Stem Cells by Mediating Interactions with a Distal Regulatory Element
Here, investigators obtained novel insights into RUNX1 function by studying regulation of the human CD34 gene, which is expressed in hematopoietic stem cells. [EMBO J] Abstract

Endurance Exercise Training Promotes Medullary Hematopoiesis
The purpose of this study was to directly investigate the effects of endurance exercise training on hematopoiesis and to identify potential mechanisms responsible for any observed changes. [FASEB J] Abstract

CLINICAL RESEARCH

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children with Sickle Cell Anemia
HUSTLE (NCT00305175) was designed to provide first-dose pharmacokinetics (PK) data for children with sickle cell anemia initiating hydroxyurea therapy, to investigate pharmacodynamics (PD) parameters including fetal hemoglobin response and maximum tolerated dose after standardized dose escalation, and to evaluate pharmacogenetics influences on PK and PD parameters. [Blood] Abstract

Treating Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Similarly to Classical Hodgkin Lymphoma with ABVD May Improve Outcome
Herein, scientists compared the outcome of patients with limited stage nodular lymphocyte predominant Hodgkin lymphoma treated in an era in which ABVD chemotherapy was routinely incorporated into the primary therapy to an earlier era in which radiotherapy was used as a single modality. [Blood] Abstract

Prognostic Implications of the IDH1 Synonymous SNP rs11554137 in Pediatric/Adult AML: A Report from the Children’s Oncology Group and SWOG
Researchers aimed to determine the prevalence, clinical associations, and prognostic significance of SNP rs11554137 in unselected pediatric and adult acute myeloid luekmia (AML) patients. [Blood] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with t(6;9)(p23;q34) Dramatically Improves the Patient Prognosis: A Matched-Pair Analysis
Investigators conducted a matched-pair analysis of de novo acute myeloid leukemia patients with and without t(6;9)(p23;q34) using data obtained from the Japanese hematopoietic stem cell transplantation data registry. [Leukemia] Abstract

Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency
Gene therapy for X-linked severe combined immunodeficiency without myelosuppressive conditioning effectively restored T cell immunity and was associated with high survival rates for up to 9 years. [Sci Transl Med] Abstract | Press Release

Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction
Here, six children were treated with autologous CD34-positive hematopoietic bone marrow stem and progenitor cells transduced with a conventional gamma retroviral vector encoding the human adenosine deaminase gene. [Sci Transl Med] Abstract | Press Release

Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase III Confirmatory Study of Marqibo® in Newly Diagnosed Acute Lymphoblastic Leukemia
Talon Therapeutics, Inc. announced that the company has reached an agreement with the U. S. Food and Drug Administration regarding a special protocol assessment for its planned Phase III study of Marqibo® (vincristine sulfate liposomes injection) in adults with newly diagnosed Philadelphia chromosome negative acute lymphoblastic leukemia. [Talon Therapeutics, Inc.] Press Release

FDA Approves New Lymphoma Drug Based on Miller School Research
The U.S. Food and Drug Administration (FDA) just approved a new drug which was based on an antibody developed at the Miller School of Medicine and has proven effective in recent clinical trials against Hodgkin’s lymphoma and anaplastic large cell lymphoma in patients for whom standard therapies failed. [University of Miami Health System] Press Release

UC Davis Awarded Five Therapy Development Stem Cell Grants
The California Institute for Regenerative Medicine approved research planning grants for five University of California, Davis (UC Davis) Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington’s disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children. [University of California, Davis School of Medicine] Press Release

Price Discount Means NICE Can Recommend a New Drug for Chronic Myeloid Leukemia
In new draft guidance the National Institute for Health and Clinical Excellence (NICE) has recommended nilotinib, also known as Tasigna, for the treatment of the chronic and accelerated phases of chronic myeloid leukemia that is resistant or intolerant to standard-dose imatinib. [National Institute for Health and Clinical Excellence, United Kingdom] Press Release

International Program Expands Efforts to Improve Blood Transfusion Safety
The National Heart, Lung, and Blood Institute has launched an $87.2 million international research program to extend a highly successful program assessing blood banking and transfusion medicine. Research conducted under the seven-year program will focus on improving transfusion benefits and reducing its risks. [National Heart, Lung, and Blood Institute, United States] Press Release

Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 [The Center for Biologics Evaluation and Research, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 4th Annual Maryland Stem Cell Research Symposium
October 6, 2011
Towson, United States

NEW American Association for Cancer Research: Translational Cancer Research for Basic Scientists
October 30-November 4, 2011
Boston, United States

Visit our events page to see a complete list of events in the hematopoietic community

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.